TY - JOUR
T1 - Optimal sampling in derivation studies was associated with improved discrimination in external validation for heart failure prognostic models
AU - the investigators for the WET-NaDEF Collaboration Project
AU - Iwakami, Naotsugu
AU - Nagai, Toshiyuki
AU - Furukawa, Toshiaki A.
AU - Tajika, Aran
AU - Onishi, Akira
AU - Nishimura, Kunihiro
AU - Ogata, Soshiro
AU - Nakai, Michikazu
AU - Takegami, Misa
AU - Nakano, Hiroki
AU - Kawasaki, Yohei
AU - Alba, Ana Carolina
AU - Guyatt, Gordon Henry
AU - Shiraishi, Yasuyuki
AU - Kohsaka, Shun
AU - Kohno, Takashi
AU - Goda, Ayumi
AU - Mizuno, Atsushi
AU - Yoshikawa, Tsutomu
AU - Anzai, Toshihisa
N1 - Funding Information:
Funding Statement: The WET-NaDEF collaboration project was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (Japan Society for the Promotion of Science [JSPS KAKENHI]), in Tokyo, Japan, Grant 23591062 and 26461088 (Dr. Yoshikawa); Grants-in-Aid for Young Scientists from JSPS KAKENHI, Grant 15K19402 (Dr. Nagai) and 18K15860 (Dr. Shiraishi); a Japan Health Labour Sciences Research, in Tokyo, Japan, Grant 14528506 (Dr. Yoshikawa); and the Sakakibara Clinical Research Grant for Promotion of Sciences, Japan, 2012, 2013, and 2014 (Dr. Yoshikawa); a grant from the Japan Agency for Medical Research and Development, in Tokyo, Japan, Grant 201439013C (Dr. Kohsaka), and a grant from the Japan Cardiovascular Research Foundation, in Tokyo, Japan, Grant 24-4-2 (Dr. Anzai). The funders played no role in conducting the research. Disclosures: Dr. Furukawa reported personal fees from Meiji Seika, grants and personal fees from Mitsubishi-Tanabe, personal fees from MSD, personal fees from Pfizer, outside the submitted work. Dr. Kohsaka reported grants and personal fees from Bayer Yakuhin, grants from Daiichi Sankyo, personal fees from Bristol-Myers Squibb/Pfizer, outside the submitted work. All the other authors reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/5
Y1 - 2020/5
N2 - Objectives: The objective of the study was to identify determinants of external validity of prognostic models. Study Design and Setting: We systematically searched for studies reporting prognostic models of heart failure (HF) and examined their performance for predicting 30-day death in a cohort of consecutive 3,452 acute HF patients. We applied published critical appraisal tools and examined whether bias or other characteristics of original derivation studies determined model performance. Results: We identified 224 models from 6,354 eligible studies. The mean c-statistic in the cohort was 0.64 (standard deviation, 0.07). In univariable analyses, only optimal sampling assessed by an adequate and valid description of the sampling frame and recruitment details to collect the population of interest (total score range: 0–2, higher scores indicating lower risk of bias) was associated with high performance (standardized β = 0.25, 95% CI: 0.12 to 0.38, P < 0.001). It was still significant after adjustment for relevant study characteristics, such as data source, scale of study, stage of illness, and study year (standardized β = 0.24, 95% CI: 0.07 to 0.40, P = 0.01). Conclusion: Optimal sampling representing the gap between the population of interest and the studied population in derivation studies was a key determinant of external validity of HF prognostic models.
AB - Objectives: The objective of the study was to identify determinants of external validity of prognostic models. Study Design and Setting: We systematically searched for studies reporting prognostic models of heart failure (HF) and examined their performance for predicting 30-day death in a cohort of consecutive 3,452 acute HF patients. We applied published critical appraisal tools and examined whether bias or other characteristics of original derivation studies determined model performance. Results: We identified 224 models from 6,354 eligible studies. The mean c-statistic in the cohort was 0.64 (standard deviation, 0.07). In univariable analyses, only optimal sampling assessed by an adequate and valid description of the sampling frame and recruitment details to collect the population of interest (total score range: 0–2, higher scores indicating lower risk of bias) was associated with high performance (standardized β = 0.25, 95% CI: 0.12 to 0.38, P < 0.001). It was still significant after adjustment for relevant study characteristics, such as data source, scale of study, stage of illness, and study year (standardized β = 0.24, 95% CI: 0.07 to 0.40, P = 0.01). Conclusion: Optimal sampling representing the gap between the population of interest and the studied population in derivation studies was a key determinant of external validity of HF prognostic models.
KW - External validation
KW - Heart failure
KW - Mortality
KW - Prediction
KW - Prognosis
KW - Prognostic model
KW - Study bias
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85079898921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079898921&partnerID=8YFLogxK
U2 - 10.1016/j.jclinepi.2020.01.011
DO - 10.1016/j.jclinepi.2020.01.011
M3 - Article
C2 - 32004670
AN - SCOPUS:85079898921
SN - 0895-4356
VL - 121
SP - 71
EP - 80
JO - Journal of Chronic Diseases
JF - Journal of Chronic Diseases
ER -